Dr. Reddy's And Senores Pharmaceuticals Inc. Launches Ivermectin Tablets In U.S. Market Equivalent To STROMECTOL®

Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. have announced the U.S. launch of Ivermectin Tablets USP, 3 mg. The product is bioequivalent and therapeutically equivalent to STROMECTOL® Tablets by Merck Sharp & Dohme LLC. Dr. Reddy's will handle the marketing of the tablets in the U.S.

Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited, said in a statement, “We are pleased to advance our growth with the launch of a limited-competition product. With our continuous focus on niche opportunities, we are proud to be the second generic to receive approval for this product.”

According to IQVIA data, the combined sales of brand-name and generic Ivermectin tablets 3 mg in the U.S. reached approximately $20 million MAT for the 12 months ending September 2024.